In last trading session, Kala Pharmaceuticals, Inc. (NASDAQ:KALA) saw 1,292,016 shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $8.61 trading at $0.56 or 6.96% at ring of the bell on the day assigns it a market valuation of $482.68 Million. That closing price of KALA’s stock is at a discount of -70.5% from its 52-week high price of $14.68 and is indicating a premium of 62.37% from its 52-week low price of $3.24. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.31 Million shares which gives us an average trading volume of 932.68 Million if we extend that period to 3-months.
For Kala Pharmaceuticals, Inc. (KALA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.4. Splitting up the data highlights that, out of 7 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 6 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.44 in the current quarter.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) trade information
Wall Street analysts have assigned a consensus price target of $19.71 to the stock, which implies a rise of 128.92% to its current value. Analysts have been projecting $10 as a low price target for the stock while placing it at a high target of $39. It follows that stock’s current price would jump +352.96% in reaching the projected high whereas dropping to the targeted low would mean a loss of 16.14% for stock’s current value.
Kala Pharmaceuticals, Inc. (KALA) estimates and forecasts
Statistics highlight that Kala Pharmaceuticals, Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company added +24.78% of value to its shares in past 6 months, showing an annual growth rate of -37.68% while that of industry is 13.7. Apart from that, the company came raising its revenue forecast for fiscal year 2020. The company is estimating its revenue growth to increase by 35.3% in the current quarter and calculating 33.3% increase in the next quarter. This year revenue growth is estimated to rise 20.3% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $2.05 Million for the same. And 6 analysts are in estimates of company making revenue of $3.33 Million in the next quarter that will end in December 01, 2020. Company posted $1.45 Million and $1.18 Million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 41.3% while estimating it to be 182.2% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -27.1% during past 5 years. In 2020, company’s earnings growth rate is likely to be around -10.6% while estimates for its earnings growth in next 5 years are of 0%
Kala Pharmaceuticals, Inc. (NASDAQ:KALA)’s Major holders
Insiders are in possession of 0.98% of company’s total shares while institution are holding 67.19% percent of that, with stock having share float percentage of 67.85%. Investors also watch the number of corporate investors in a company very closely, which is 116 institutions for Kala Pharmaceuticals, Inc. that are currently holding shares of the company. RA Capital Management, L.P. is the top institutional holder at KALA for having 10.87 Million shares of worth $114.29 Million. And as of June 29, 2020, it was holding 19.4% of the company’s outstanding shares.
The second largest institutional holder is Orbimed Advisors LLC., which was holding about 5.4 Million shares on June 29, 2020. The number of shares represents firm’s hold over 9.64% of outstanding shares, having a total worth of $56.78 Million.
On the other hand, Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and Fidelity Mid-Cap Stock Fund are the top two Mutual Funds which own company’s shares. As of June 29, 2020, the former fund manager was holding 3450000 shares of worth $36.26 Million or 6.15% of the total outstanding shares. The later fund manager was in possession of 1.13 Million shares on June 29, 2020, making its stake of worth around $11.9 Million in the company or a holder of 2.02% of company’s stock.